3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
CNS
1
Conditions
Ovarian Neoplasms
9
Neoplasms
3
Endometrial Neoplasms
3
Breast Neoplasms
3
Prostatic Neoplasms
2
Pancreatic Neoplasms
2
Head and Neck Neoplasms
2
Esophageal Neoplasms
2
Uterine Cervical Neoplasms
1
Urologic Neoplasms
1
Thrombocytopenia
1
Stomach Neoplasms
1
Solid Tumor, Adult
1
Recurrence
1
Rectal Neoplasms
1
Osteosarcoma
1
Oligodendroglioma
1
Neutropenia
1
Neuroblastoma
1
Neoplasm Metastasis
1
Melanoma
1
Lung Neoplasms
1
Glioma
1
Glioblastoma
1
Fallopian Tube Neoplasms
1
Cystadenocarcinoma, Serous
1
Colonic Neoplasms
1
Carcinoma, Renal Cell
1
Biliary Tract Neoplasms
1
Astrocytoma
1
Interventions
Temozolomide
17
Radiotherapy
5
Bevacizumab
5
Filgrastim
4
vocimagene amiretrorepvec
3
sargramostim
3
etoposide phosphate
3
antineoplaston AS 2-1
3
antineoplaston A10
3
Surgical Procedures, Operative
3
O(6)-benzylguanine
3
Melphalan
3
Lomustine
3
Flucytosine
3
Dynamic Contrast Enhanced Magnetic Resonance Imaging
3
Carmustine
3
Aminolevulinic Acid
3
2-phenyl-6-(2'-(4'-(ethoxycarbonyl)thiazolyl))thiazolo(3,2-b)(1,2,4)triazole
3
tovorafenib
2
palbociclib
2
cabozantinib
2
Vorinostat
2
Topotecan
2
Thiotepa
2
Radiotherapy, Intensity-Modulated
2
Perfusion Magnetic Resonance Imaging
2
Magnetic Resonance Spectroscopy
2
Irinotecan
2
Ifosfamide
2
Granulocyte Colony-Stimulating Factor
2
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Terminated
×
Astrocytoma
×
niraparib
×
Clear all
NCT05297864
2025-05-23
OU-SCC-PI-4G
University of Oklahoma
Phase 2
Terminated
15 enrolled
13 charts